32 related articles for article (PubMed ID: 38616411)
1. A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience.
Gallimore AR; Strassman RJ
Front Pharmacol; 2016; 7():211. PubMed ID: 27471468
[TBL] [Abstract][Full Text] [Related]
2. Novel extended-release transdermal formulations of the psychedelic N,N-dimethyltryptamine (DMT).
Witowski CG; Hess MR; Jones NT; Pellitteri Hahn MC; Razidlo J; Bhavsar R; Beer C; Gonzalez-Velazquez N; Scarlett CO; Wenthur CJ; von Salm JL
Eur J Pharm Sci; 2024 May; 199():106803. PubMed ID: 38788435
[TBL] [Abstract][Full Text] [Related]
3. The flattening of spacetime hierarchy of the
Vohryzek J; Cabral J; Timmermann C; Atasoy S; Roseman L; Nutt DJ; Carhart-Harris RL; Deco G; Kringelbach ML
Natl Sci Rev; 2024 May; 11(5):nwae124. PubMed ID: 38778818
[TBL] [Abstract][Full Text] [Related]
4. A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers.
Reckweg J; Mason NL; van Leeuwen C; Toennes SW; Terwey TH; Ramaekers JG
Front Pharmacol; 2021; 12():760671. PubMed ID: 34912222
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial.
James E; Erritzoe D; Benway T; Joel Z; Timmermann C; Good M; Agnorelli C; Weiss BM; Barba T; Campbell G; Baker Jones M; Hughes C; Topping H; Boyce M; Routledge C
Front Psychiatry; 2023; 14():1305796. PubMed ID: 38274414
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.
Jiang XL; Shen HW; Mager DE; Yu AM
Drug Metab Dispos; 2013 May; 41(5):975-86. PubMed ID: 23393220
[TBL] [Abstract][Full Text] [Related]
7. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
Shen HW; Wu C; Jiang XL; Yu AM
Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
[TBL] [Abstract][Full Text] [Related]
8. Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study.
Shen HW; Jiang XL; Yu AM
Bioanalysis; 2009 Apr; 1(1):87-95. PubMed ID: 20523750
[TBL] [Abstract][Full Text] [Related]
9. Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-
Rucker JJ; Roberts C; Seynaeve M; Young AH; Suttle B; Yamamoto T; Ermakova AO; Dunbar F; Wiegand F
J Psychopharmacol; 2024 Apr; ():2698811241246857. PubMed ID: 38616411
[TBL] [Abstract][Full Text] [Related]
10. A narrative synthesis of research with 5-MeO-DMT.
Ermakova AO; Dunbar F; Rucker J; Johnson MW
J Psychopharmacol; 2022 Mar; 36(3):273-294. PubMed ID: 34666554
[TBL] [Abstract][Full Text] [Related]
11. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).
Reckweg JT; Uthaug MV; Szabo A; Davis AK; Lancelotta R; Mason NL; Ramaekers JG
J Neurochem; 2022 Jul; 162(1):128-146. PubMed ID: 35149998
[TBL] [Abstract][Full Text] [Related]
12. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
Shen HW; Jiang XL; Winter JC; Yu AM
Curr Drug Metab; 2010 Oct; 11(8):659-66. PubMed ID: 20942780
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
